Musculoskeletal Disorders

New Romosozumab BLA Includes Data from Additional Osteoporosis Trials

By July 13, 2018

Evenity is a bone-forming monoclonal antibody designed to inhibit the activity of sclerostin, which allows the drug to rapidly increase bone formation and reduce bone resorption simultaneously.

Mammography Use Tied to Other Preventive Tests in Older Women

July 09, 2018

The researchers found that women who underwent index screening mammography were more likely than unscreened women to later undergo Papanicolaou test (odds ratio, 1.49), bone mass measurement (odds ratio, 1.70), and influenza vaccine (odds ratio, 1.45).

Ezutromid Development Discontinued After DMD Trial Fails to Meet Endpoints

By June 28, 2018

Ezutromid, an oral utrophin modulator, was assessed in the 48-week PhaseOut DMD trial which included 40 boys with DMD.

USPSTF Issues Recommendation on Screening for Osteoporosis

June 28, 2018

Based on these findings, the USPSTF recommends screening for women aged 65 years and older and in younger women who have been through menopause and are at increased risk.

Muscle Spasm Treatments

June 26, 2018

Muscle spasm treatment chart with dosing regimens for muscle relaxants and other medications.

Antibiotic-Methotrexate Combo Leads to Serious Side Effects in RA Patient

By June 25, 2018

The case involved a 68-year-old female patient with rheumatoid arthritis on methotrexate 10mg weekly who presented to the emergency department with complaints of lethargy and weakness after being prescribed a 2-week course of TS for a bacterial skin infection.

New Recommendations Guide Arthritis Pain Management

June 22, 2018

Patient-centered recommendations released by the European League Against Rheumatism

Treatment of Hidradenitis Suppurativa with SAPHO Syndrome: A Case Review

By June 21, 2018

The male patient presented in 2009 with a "3-year history of multiple interconnecting comedones in the axilla and inguinal regions, as well as scarring from previous lesions."

Cosentyx Slows Progression of Joint Structural Damage in Psoriatic Arthritis

By June 20, 2018

The update is based on data from the Phase 3 FUTURE 5 study (N=996) which evaluated Cosentyx versus placebo in patients with active psoriatic arthritis.

Arthritis Treatments: NSAIDs

June 20, 2018

NSAIDS (non-steroidal anti-inflammatory drugs) indicated for the treatment of different types of arthritis.

Tattoo-Linked Complications ID'd in Immunosuppressed Female

June 19, 2018

This case details complications related to tattooing in a 31-year-old woman with a history of cystic fibrosis who had undergone bilateral lung transplantation in 2009 and was on long-term immunosuppressive therapy.

FDA Lifts Clinical Hold on Trial for Duchenne Muscular Dystrophy Treatment

By June 18, 2018

SGT-001 is a novel adeno-associated viral (AAV) vector mediated gene transfer that could potentially address the underlying genetic cause of DMD, mutations in the dystrophin gene.

Binge Drinking Tied to Poorer Bone Health in Young Females

June 15, 2018

The researchers found that frequent HED was associated with decreased vertebral bone mineral density (BMD), even when controlling for variables most commonly associated with bone health such as lean body mass, physical activity, age at menarche, smoking, and oral contraception use.

Many AKI Reports in FAERS Linked to Drugs Not Recognized as Nephrotoxic

By June 12, 2018

According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.

Does Rheumatoid Arthritis Tx Improve Mental Health Outcomes?

June 06, 2018

When the analysis was limited to studies that examined bDMARDs vs no-treatment placebo controls, bDMARDs had a substantial benefit on physical health, measured by the Physical Component Summary, compared with mental health.

Treatment for Prosthetic Joint Infections Gets FDA's QIDP Designation

By June 04, 2018

PJI is a challenging complication of joint arthroplasty with few effective treatment options.

Rheumatoid Arthritis Treatment Olumiant Gets FDA Approval

By June 01, 2018

The approval was supported by a clinical program that included dose-ranging trials (Study I and II) and confirmatory Phase 3 trials (Study III and IV).

Consensi Approved to Treat Hypertension and Osteoarthritis Pain

By June 01, 2018

Consensi combines amlodipine besylate, a calcium-channel blocker (CCB), and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID).

FDA Approves AI Algorithm That Helps Detect Wrist Fractures

By May 25, 2018

OsteoDetect is a computer-aided detection and diagnostic software that uses an algorithm to analyze 2-D wrist radiographs for signs of distal radius fracture.

Pegloticase Retreatment Effective for Gout After Gap in Therapy

By May 24, 2018

The study authors retrospectively analyzed the charts of 4 chronic gout patients from a practice-based rheumatology clinic.

Prolia Approved for Glucocorticoid-Induced Osteoporosis

By May 22, 2018

The efficacy and safety of Prolia in the treatment of patients with glucocorticoid-induced osteoporosis was assessed in the 12-month primary analysis of a 2-year, randomized, multicenter, double-blind, parallel-group, active-controlled study (N=795).

IV Tramadol Significantly Reduces Post-Op Pain in Phase 3 Study

By May 21, 2018

In this multicenter, double-blind, placebo-controlled trial, patients (N=409) were randomized 1:1:1 to a postoperative regimen of IV tramadol 50mg, IV tramadol 25mg, or placebo administered over 15 minutes at hours 0, 2, 4, and once every 4 hours thereafter (up to 13 doses).

RA Treatment During Pregnancy: Is Infection Risk Greater in Offspring?

By May 18, 2018

Offspring were followed from birth until 12 months, first indication of serious infection, end of commercial insurance eligibility, death or end of study period, whichever came first.

Adding Chiropractic to Usual Care Beneficial for Low Back Pain

May 18, 2018

"This trial provides additional support for the inclusion of chiropractic care as a component of multidisciplinary health care for low back pain, as currently recommended in existing guidelines," the authors write.

Certolizumab Pegol Beneficial in Non-Radiographic Axial Spondyloarthritis

By May 17, 2018

During the 52-week trial period, the treatment group received a 400mg dose of CZP subcutaneously at weeks 0, 2, and 4, followed by 200mg of CZP every 2 weeks starting at week 6; or placebo.

Actemra SC Approved to Treat Rare Form of Juvenile Arthritis

By May 14, 2018

Approval of the SC formulation for this patient population was supported by data from the Phase 1b JIGSAW-117 trial, a 52-week, open-label multicenter, pharmacokinetic/pharmacodynamic bridging study (N=52) that aimed to determine the appropriate dosing regimen of Actemra SC based on body weight in children with PJIA.

Corticosteroid-Related Adverse Events Examined Based on Dose, Duration

By May 14, 2018

Using a privately-insured administrative database, researchers examined a total of 78,704 patients with autoimmune or inflammatory disease diagnoses between 2006 and 2015.

Anxiety Levels Tied to Bone Mineral Density Post-Menopause

May 14, 2018

There was a significant correlation for anxiety levels with age, menopausal age, years since menopause, and depressive symptoms; multiple regression analysis predicted reduced BMD in the lumbar spine.

Adverse Effect of Osteoporosis Drug May Help Treat Hair Loss

By May 11, 2018

Researchers found that a non-immunosuppressant drug originally designed to treat osteoporosis (WAY-316606) targeted the same mechanism by antagonizing SFRP1, and after treating hair follicles with WAY-316606 for 6 days, the authors found enhanced human hair growth.

Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up

By May 11, 2018

The 1-year cardiovascular mortality hazard ratio (HR) for alendronate users was 0.33 (95% CI, 0.17 to 0.65) and 0.55 for incident myocardial infarction (95% CI, 0.34 to 0.89).